vs
QuidelOrtho Corp（QDEL）与ROYAL GOLD INC（RGLD）财务数据对比。点击上方公司名可切换其他公司
QuidelOrtho Corp的季度营收约是ROYAL GOLD INC的1.9倍（$699.9M vs $375.3M），ROYAL GOLD INC净利率更高（24.9% vs -104.7%，领先129.7%），ROYAL GOLD INC同比增速更快（85.3% vs -3.7%），过去两年ROYAL GOLD INC的营收复合增速更高（58.8% vs -2.9%）
奎德尔奥索公司是美国的诊断医疗产品制造商，旗下产品面向全球市场销售，深耕体外诊断领域，为医疗机构及相关用户提供专业的检测解决方案，助力全球医疗健康服务效率提升。
Royal Gold Inc.是全球领先的贵金属流权与特许权经营企业，收购并管理多元化的矿业项目流权、净熔炼收益特许权及相关权益，资产覆盖黄金、白银、铜等品类，业务遍及多地区，无需直接承担采矿运营风险。
QDEL vs RGLD — 直观对比
营收规模更大
QDEL
是对方的1.9倍
$375.3M
营收增速更快
RGLD
高出89.0%
-3.7%
净利率更高
RGLD
高出129.7%
-104.7%
两年增速更快
RGLD
近两年复合增速
-2.9%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $699.9M | $375.3M |
| 净利润 | $-733.0M | $93.6M |
| 毛利率 | — | 64.6% |
| 营业利润率 | -100.7% | 56.2% |
| 净利率 | -104.7% | 24.9% |
| 营收同比 | -3.7% | 85.3% |
| 净利润同比 | -3583.4% | -12.8% |
| 每股收益（稀释后） | $-10.78 | $1.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收QDELRGLD
| Q4 25 | — | $375.3M | ||
| Q3 25 | $699.9M | $252.1M | ||
| Q2 25 | $613.9M | $209.6M | ||
| Q1 25 | $692.8M | $193.4M | ||
| Q4 24 | $707.8M | $202.6M | ||
| Q3 24 | $727.1M | $193.8M | ||
| Q2 24 | $637.0M | $174.1M | ||
| Q1 24 | $711.0M | $148.9M |
净利润QDELRGLD
| Q4 25 | — | $93.6M | ||
| Q3 25 | $-733.0M | $126.8M | ||
| Q2 25 | $-255.4M | $132.3M | ||
| Q1 25 | $-12.7M | $113.5M | ||
| Q4 24 | $-178.4M | $107.4M | ||
| Q3 24 | $-19.9M | $96.2M | ||
| Q2 24 | $-147.7M | $81.2M | ||
| Q1 24 | $-1.7B | $47.2M |
毛利率QDELRGLD
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | 73.6% | ||
| Q2 25 | — | 72.6% | ||
| Q1 25 | — | 69.4% | ||
| Q4 24 | — | 70.3% | ||
| Q3 24 | — | 66.6% | ||
| Q2 24 | — | 64.7% | ||
| Q1 24 | — | 58.4% |
营业利润率QDELRGLD
| Q4 25 | — | 56.2% | ||
| Q3 25 | -100.7% | 64.4% | ||
| Q2 25 | -29.4% | 67.7% | ||
| Q1 25 | 4.7% | 63.6% | ||
| Q4 24 | -14.2% | 65.9% | ||
| Q3 24 | 2.1% | 61.3% | ||
| Q2 24 | -18.4% | 58.6% | ||
| Q1 24 | -247.3% | 50.7% |
净利率QDELRGLD
| Q4 25 | — | 24.9% | ||
| Q3 25 | -104.7% | 50.3% | ||
| Q2 25 | -41.6% | 63.1% | ||
| Q1 25 | -1.8% | 58.7% | ||
| Q4 24 | -25.2% | 53.0% | ||
| Q3 24 | -2.7% | 49.7% | ||
| Q2 24 | -23.2% | 46.6% | ||
| Q1 24 | -239.9% | 31.7% |
每股收益（稀释后）QDELRGLD
| Q4 25 | — | $1.04 | ||
| Q3 25 | $-10.78 | $1.92 | ||
| Q2 25 | $-3.77 | $2.01 | ||
| Q1 25 | $-0.19 | $1.72 | ||
| Q4 24 | $-2.54 | $1.63 | ||
| Q3 24 | $-0.30 | $1.46 | ||
| Q2 24 | $-2.20 | $1.23 | ||
| Q1 24 | $-25.50 | $0.72 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $98.1M | $233.7M |
| 总债务越低越好 | $2.5B | — |
| 股东权益账面价值 | $2.0B | $7.2B |
| 总资产 | $5.7B | $9.5B |
| 负债/权益比越低杠杆越低 | 1.23× | — |
8季度趋势，按日历期对齐
现金及短期投资QDELRGLD
| Q4 25 | — | $233.7M | ||
| Q3 25 | $98.1M | $172.8M | ||
| Q2 25 | $151.7M | $248.2M | ||
| Q1 25 | $127.1M | $240.8M | ||
| Q4 24 | $98.3M | $195.5M | ||
| Q3 24 | $143.7M | $127.9M | ||
| Q2 24 | $107.0M | $74.2M | ||
| Q1 24 | $78.5M | $137.9M |
总债务QDELRGLD
| Q4 25 | — | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.1B | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.2B | $0 | ||
| Q2 24 | $2.2B | $50.0M | ||
| Q1 24 | $2.2B | — |
股东权益QDELRGLD
| Q4 25 | — | $7.2B | ||
| Q3 25 | $2.0B | $3.4B | ||
| Q2 25 | $2.8B | $3.3B | ||
| Q1 25 | $3.0B | $3.2B | ||
| Q4 24 | $3.0B | $3.1B | ||
| Q3 24 | $3.2B | $3.0B | ||
| Q2 24 | $3.2B | $3.0B | ||
| Q1 24 | $3.3B | $2.9B |
总资产QDELRGLD
| Q4 25 | — | $9.5B | ||
| Q3 25 | $5.7B | $4.5B | ||
| Q2 25 | $6.4B | $3.6B | ||
| Q1 25 | $6.5B | $3.5B | ||
| Q4 24 | $6.4B | $3.4B | ||
| Q3 24 | $6.8B | $3.3B | ||
| Q2 24 | $6.7B | $3.3B | ||
| Q1 24 | $6.7B | $3.3B |
负债/权益比QDELRGLD
| Q4 25 | — | — | ||
| Q3 25 | 1.23× | — | ||
| Q2 25 | 0.74× | — | ||
| Q1 25 | 0.70× | — | ||
| Q4 24 | 0.72× | — | ||
| Q3 24 | 0.68× | 0.00× | ||
| Q2 24 | 0.70× | 0.02× | ||
| Q1 24 | 0.68× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-45.5M | $241.7M |
| 自由现金流经营现金流 - 资本支出 | $-94.7M | — |
| 自由现金流率自由现金流/营收 | -13.5% | — |
| 资本支出强度资本支出/营收 | 7.0% | — |
| 现金转化率经营现金流/净利润 | — | 2.58× |
| 过去12个月自由现金流最近4个季度 | $-153.1M | — |
8季度趋势，按日历期对齐
经营现金流QDELRGLD
| Q4 25 | — | $241.7M | ||
| Q3 25 | $-45.5M | $174.0M | ||
| Q2 25 | $-46.8M | $152.8M | ||
| Q1 25 | $65.6M | $136.4M | ||
| Q4 24 | $63.7M | $141.1M | ||
| Q3 24 | $117.9M | $136.7M | ||
| Q2 24 | $-97.9M | $113.5M | ||
| Q1 24 | $-700.0K | $138.3M |
自由现金流QDELRGLD
| Q4 25 | — | — | ||
| Q3 25 | $-94.7M | — | ||
| Q2 25 | $-84.3M | — | ||
| Q1 25 | $9.4M | — | ||
| Q4 24 | $16.5M | — | ||
| Q3 24 | $71.4M | — | ||
| Q2 24 | $-133.2M | — | ||
| Q1 24 | $-66.8M | — |
自由现金流率QDELRGLD
| Q4 25 | — | — | ||
| Q3 25 | -13.5% | — | ||
| Q2 25 | -13.7% | — | ||
| Q1 25 | 1.4% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 9.8% | — | ||
| Q2 24 | -20.9% | — | ||
| Q1 24 | -9.4% | — |
资本支出强度QDELRGLD
| Q4 25 | — | — | ||
| Q3 25 | 7.0% | — | ||
| Q2 25 | 6.1% | — | ||
| Q1 25 | 8.1% | — | ||
| Q4 24 | 6.7% | — | ||
| Q3 24 | 6.4% | — | ||
| Q2 24 | 5.5% | — | ||
| Q1 24 | 9.3% | — |
现金转化率QDELRGLD
| Q4 25 | — | 2.58× | ||
| Q3 25 | — | 1.37× | ||
| Q2 25 | — | 1.15× | ||
| Q1 25 | — | 1.20× | ||
| Q4 24 | — | 1.31× | ||
| Q3 24 | — | 1.42× | ||
| Q2 24 | — | 1.40× | ||
| Q1 24 | — | 2.93× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
RGLD
| Gold | $216.9M | 58% |
| Pueblo Viejo | $47.3M | 13% |
| Andacollo | $32.6M | 9% |
| Silver | $32.1M | 9% |
| Other | $27.2M | 7% |
| Copper | $13.7M | 4% |
| Cortez Legacy Zone | $5.4M | 1% |
